Category Archives: Stem Cell Research

SAN FRANCISCO, June 3, 2020 /PRNewswire/ --The global cell expansion marketsize is expected to reach USD 39.7 billion by 2027 registering a CAGR of 9.4%, according to a new report by Grand View Research, Inc. Cell expansion techniques are increasingly employed for the development of cellular and gene therapies from a single cord blood collection. These techniques can also be used for the expansion of stored Stem Cells (SCs) for the development of cancer therapies. Therefore, significant developments in cord blood SCs expansion technologies are expected to boost market growth.

Key suggestions from the report:

Read 170 page research report with ToC on "Cell Expansion Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables), By Cell Type (Mammalian, Animal), By Application, By End Use, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/cell-expansion-market

Companies have made heavy investments for the expansion of tissue-engineered products and the development of biologics. For instance, in March 2019, Merck KGaA invested USD 168 million for the expansion of its biologics manufacturing facility in Switzerland. Such initiatives are expected to boost the demand for solutions required for biologic development, thereby leading to market growth.

Bioreactors are fundamental tools in this market. Extensive research studies related to the applications of bioreactor engineering approaches have led to the incorporation of novel culture technologies. Moreover, the combined use of automated bioreactors with the microcarrier technology leads to an efficient expansion and enrichment of the cancer SCs. As a result, these approaches have gained immense traction in this market.

Grand View Research has segmented the global cell expansion market on the basis of product, cell type, application, end use, and region:

Find more research reports on Biotechnology Industry, by Grand View Research:

Gain access to Grand View Compass,our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected] Web: https://www.grandviewresearch.com Follow Us: LinkedIn | Twitter

SOURCE Grand View Research, Inc.

See the original post:
Cell Expansion Market Worth $39.7 Billion by 2027 l CAGR 9.4%: Grand View Research, Inc. - PRNewswire

At the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, speaker Leslie R. Ellis, MD, MSHPEd, FACP, associate professor of medicine, Wake Forest Baptist Health, Comprehensive Cancer Center Winston-Salem, discussed the results of studies in a session looking into current research on leukemia, myelodysplastic syndromes (MDS), and allotransplant.1

Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax

The first study discussed was the phase 1b/2 trial looking into the adverse effects and dosing of venetoclax when paired with ivosidenib, with or without being paired with azacitidine additionally. These treatments were used with participants in the study who had IDH1-mutated hematologic malignancies.1,2

The results demonstrated that venetoclax and ivosidenib may stop cancer cell growth by blocking some of the enzymes necessary for cell growth. In chemotherapy, drugs such as azacytidine work differently by hindering growth of cancer cells through either killing the cells, stopping them from dividing, or stopping them from spreading.1,2

The researchers found that treatment with ivosidenib and venetoclax with azacitidine may be more effective when treating patients with IDH1-mutated AML, compared with ivosidenib and venetoclax alone. Ellis added that the results demonstrated that further follow up and accrual would be ongoing in order to better define the duration and biomarkers of response in patients.1,2

OPTIC Study of Ponatinib for Chronic Phase-CML

The second study discussed in the session was the phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial evaluating response-based dosing regimens of ponatinib over a range of 3 starting doses (45 mg, 30 mg, 15 mg).1,3

The aim of the study was to optimize the treatments efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who were found to be resistant or intolerant to tyrosine kinase inhibitor therapy.1,3

With median follow-up time of approximately 21 months, data from the interim analysis demonstrated that the optimal benefit-risk profile for ponatinib in patients with CP-CML was observed at a daily starting dose of 45 mg followed by a reduction to 15 mg after achieving 1% BCR-ABL1. Following this dose reduction to 15 mg/day, the optimal benefit to treatment was demonstrated to be maintained by patients. This dosing regimen was also found to result in an adjudicated arterial occlusive event rate of 5.3%.1,3

Ellis explained that the complete primary analysis of the trial will occur after all patients are able to have at least 12 months of follow-up, with the resulting data being presented following this occurrence.1,3

Pediatric Disease Risk Index for Allogeneic Stem Cell Transplantation

In the final study discussed during the session, Ellis presented a recently developed validated pediatric disease risk index (p-DRI) for acute myeloid (AML) and acute lymphoblastic leukemia (ALL) that provides a stratification of children receiving allogeneic hematopoietic cell transplantation for prognostication.1,4

Characteristics such as disease, disease status, and cytogenetic abnormalities are known to effect relapse and survival in patients following transplantation for AML and ALL. It has previously been observed in adults that these attributes can be used to develop a disease risk index for survival. For this reason, the analysis conducted was aimed to develop and validate a p-DRI.1,4

Patients who were younger than 18 years with AML and ALL transplanted between 2008 and 2017 in the United States were eligible for the p-DRI, with separate analyses performed for both AML and ALL. Each patient was randomly assigned to a training and validation cohort.1,4

In order to select significant variables, the researchers used the Cox proportional hazards model with stepwise selection. The primary outcome was leukemia-free survival (LFS).1,4

There were 4 risk groups identified for AML and 3 risk groups for ALL. The probabilities over 5 years of LFS for AML were 81%, 56%, 44%, and 21% for good, intermediate, high, and very high-risk groups, respectively. For ALL, the probabilities over 5 years of LFS for ALL were 68%, 50%, and 15% for good, intermediate, high risk groups, respectively.1,4

Ellis explained that based on these results, the researchers were able to validate that the p-DRI effectively stratified children with AML and ALL for prognostication undergoing allogeneic transplantation.1,4

REFERENCES

Original post:
Highlights of Current Research on Leukemia, MDS, and Allotransplant - Pharmacy Times

The latest report pertaining to Stem Cell Characterization and Analysis Tool Market now available with Market Study Report, LLC, provides a detailed analysis regarding market size, revenue estimations and growth rate of the industry. In addition, the report illustrates the major obstacles and newest growth strategies adopted by leading manufacturers who are a part of the competitive landscape of this market.

.

Request a sample Report of Stem Cell Characterization and Analysis Tool Market at:https://www.marketstudyreport.com/request-a-sample/2679261?utm_source=bulletinline&utm_medium=ADS

The latest report on the Stem Cell Characterization and Analysis Tool market contains a detailed analysis of this marketplace and entails information about various industry segmentations. According to the report, the market is presumed to amass substantial revenue by the end of the forecast duration while expanding at decent growth rate.

Details regarding the industry size, remuneration potential, and volume share are compiled in the report. It further lists out the drivers and challenges that will impact the growth of Stem Cell Characterization and Analysis Tool market during the estimated timeframe.

The Stem Cell Characterization and Analysis Tool market with respect to the geographical terrain:

Ask for Discount on Stem Cell Characterization and Analysis Tool Market Report at:https://www.marketstudyreport.com/check-for-discount/2679261?utm_source=bulletinline&utm_medium=ADS

Additional highlights from the Stem Cell Characterization and Analysis Tool market share report are enlisted below:

Table of Contents:

Executive Summary: It includes key trends of the Stem Cell Characterization and Analysis Tool market share related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Stem Cell Characterization and Analysis Tool market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Stem Cell Characterization and Analysis Tool market.

Market Segments: This part of the report discusses about product type and application segments of the Stem Cell Characterization and Analysis Tool market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-stem-cell-characterization-and-analysis-tool-market-2020-by-company-regions-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Stem Cell Characterization and Analysis Tool Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Stem Cell Characterization and Analysis Tool Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Related Reports:

1. Global Sterile Vial Adaptor Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025The Sterile Vial Adaptor Market Report offer the complete scenario of the industry and valuation of upcoming Trends for future market. It also gives the analytic of enduring growth factor, trends and statistic of Sterile Vial Adaptor Market industry. The Sterile Vial Adaptor Market has been outlined by overall information and analysis.Read More: https://www.marketstudyreport.com/reports/global-sterile-vial-adaptor-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Protective Medical Gowns Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Protective Medical Gowns Market report starts from illustration of Industry Chain structure, and portrays industry condition, at that point investigations advertise size and figure of Protective Medical Gowns by item, district and application, likewise, this report presents showcase rivalry circumstance among the merchants profile, plus, advertise value examination and esteem chain highlights are canvassed in this report.Read More: https://www.marketstudyreport.com/reports/global-protective-medical-gowns-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Read More Reports On: https://www.marketwatch.com/press-release/51-growth-for-extracorporeal-shock-wave-lithotripter-market-size-raising-to-usd-470-million-by-2025-2020-03-19?tesla=y

Read More Reports On: https://www.marketwatch.com/press-release/at-38-cagr-hazardous-area-signaling-devices-market-size-set-to-register-2170-million-usd-by-2025-2020-03-23?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post:
Unexpected Growth Seen in Stem Cell Characterization and Analysis Tool Market from 2020 to 2025 - Bulletin Line

WASHINGTON, June 3, 2020 /PRNewswire/ --A new systematic review and meta-analysis of clinical studies using mesenchymal stromal cells (MSCs) led by a team at the Mayo Clinic, and including researchers from Emory, Duke, Case-Western, and the University of Miami, shows a trend toward improved outcomes and reduced mortality for patients with acute respiratory distress syndrome (ARDS), a major complication for patients with COVID-19. This studyand several othersalso have shown that MSCs are safe for patients.

Based on these findings, the authors call for the rapid commencement of large-scale, confirmatory clinical trials to build on the existing evidence base, which shows a trend toward improved pulmonary function and reduced severe lung inflammation for patients with ARDS, paving the way toward another treatment option for seriously ill patients with COVID-19.

To date, nearly two million Americans have tested positive for COVID-19 and more than 100,000 Americans have died. In its most severe form, COVID-19 leads to ARDSa life-threatening lung injury that allows fluid to leak into the lungs and makes it difficult for patients to breathe. More than 40 percent of individuals hospitalized for severe and critical COVID-19 develop ARDS, and 22 percent to 62 percent of those who are diagnosed and become critically ill, die from the disease. There is no effective treatment for ARDS today; MSCs potentially offer a unique therapeutic option to help patients in need.

"The analysis shows a positive trend in outcomes when treating ARDS patients with MSC therapy and represents the potential to save thousands of patients with COVID-19 induced ARDS," said Wenchun Qu, MD, PhD of the Mayo Clinic and first author of the paper. "The potential benefitcombined with the demonstrated safety of these therapiessupports the need for rapid commencement of more clinical trials."

"Acute respiratory distress syndrome is a rapidly progressive disease that can occur in critically ill patients," said Anthony Atala, MD, Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "Having additional potential therapies, such as MSCs, could be highly beneficial to patients with COVID-19."

To date, the FDA has approved more than a dozen investigational new drug applications for the use of MSCs for COVID-19-related conditions. The National Institutes of Health (NIH) has also supported the use of MSCs and other regenerative cell therapies to help patients with other conditions. The bipartisan 21st Century Cures Act provided $30 million in funding to the NIH over three years for clinical research for such therapies. However, these limited investments expire in fiscal year 2020.

The Alliance for Cell Therapy Now and the Regenerative Medicine Foundation support the recommendation of the authors, who urge funding for larger studies that build on the results to date. Collaboration and funding are also needed to collect and analyze the evidence from multiple ongoing and new studies, to better evaluate outcomes and potential benefits of MSC therapy for COVID-19 patients in need. A portion of the more than $10 billion in funding directed by Congress to the Biomedical Advanced Research and Development Authority (BARDA) and the NIH for COVID-19 should be used to support these goals.

About the Alliance for Cell Therapy Now

Alliance for Cell Therapy Now (ACT Now) is an independent, non-profit organization devoted to advancing the availability of and access to safe and effective cell therapies for patients in need. ACT Now convenes experts and stakeholders to develop and advance sound policies that will improve the development, manufacturing, delivery, and improvement of regenerative cell therapies. See http://allianceforcelltherapynow.org/

About the Regenerative Medicine Foundation

The non-profit Regenerative Medicine Foundation (RMF) fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honoring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives. STEM CELLS Translational Medicine is RMF's official journal partner. See https://www.regmedfoundation.org/

View original content:http://www.prnewswire.com/news-releases/msc-therapy-for-acute-respiratory-distress-syndrome-its-time-to-accelerate-clinical-trials-for-covid-19-patients-in-need-301070329.html

SOURCE Alliance for Cell Therapy Now

Go here to see the original:
MSC Therapy for Acute Respiratory Distress Syndrome; It's Time to Accelerate Clinical Trials for COVID-19 Patients in Need - P&T Community

Human Mesenchymal Stem Cells (hMSC) Market Sales 2020-2026

Worldwide Human Mesenchymal Stem Cells (hMSC) Market Report 2020-2026 is a systematic and insightful compilation of valuable evaluations of Human Mesenchymal Stem Cells (hMSC) market and relevant aspects. The report offers an in depth exploration of the market and its scope, trends, structure, production, profitability and maturity.

The precise evaluation of market size, share, revenue, sales volume, demand, and rate of growth involved within the report drive investors, industry experts, researchers, also as novice and well-established market players to grasp the general Human Mesenchymal Stem Cells (hMSC) market structure.

Report: calibreresearch.com/report/est-sample The Human Mesenchymal Stem Cells (hMSC) market report also delivers an in-depth analysis of the emerging industry trends along side the restraints, key players, and opportunities within the Human Mesenchymal Stem Cells (hMSC) market to supply worthwhile insights also as a gift scenario for generating right decision.

Moreover, the new report on the Human Mesenchymal Stem Cells (hMSC) industry covers the prominent vendors within the universal market alongside SWOT analysis, fiscal overview and major developments. The world Human Mesenchymal Stem Cells (hMSC) Market report is considered as a detailed investigation of the respective market that will provide key solutions for establishment of profit-driven business strategies.

It is helpful for offering details about futuristic Human Mesenchymal Stem Cells (hMSC) industry trends and in-depth assessment of the international industry. It permits you to determine remarkable challenges and risk factors alongside major opportunities available in the world Human Mesenchymal Stem Cells (hMSC) market.

This report also exhibits the whole historical and current status of the Human Mesenchymal Stem Cells (hMSC) Market worldly. Apart from this, the report on the Human Mesenchymal Stem Cells (hMSC) industry also represents the graphical representation of the upcoming Human Mesenchymal Stem Cells (hMSC) Market infrastructure and the Compound Annual Growth Rate (CAGR) in detail.

Report: calibreresearch.com/report/for-buying

The report on the Human Mesenchymal Stem Cells (hMSC) market is an exclusive and deep study which delivers a comprehensive overview of the industry contains the recent trends and future proportions of the Human Mesenchymal Stem Cells (hMSC) market in terms of product and services. Meanwhile, this report offers a professional research study on the Human Mesenchymal Stem Cells (hMSC) market so as to guage the remarkable vendors by calibrating all the relevant products or services to know the positioning of the key players within the Human Mesenchymal Stem Cells (hMSC) market worldly.

Leading companies reviewed in the Human Mesenchymal Stem Cells (hMSC) report are: PromoCell ThermoFisher KURABO Lifeline Cell Technology Merck The Human Mesenchymal Stem Cells (hMSC) Market report is segmented into following categories: The product segment of the report offers product market information such as demand, supply and market value of the product. The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.

The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Type by following categories; Umbilical Cord Matrix hMSC Bone Marrow hMSC Adipose Tissue hMSC Other The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Application by following categories; Medical Application Research Other Applications

Report: calibreresearch.com/report/est-sample

The world Human Mesenchymal Stem Cells (hMSC) marketing research report offers an in depth summary of the foremost desirable factors and informative details about the universal industry. Moreover, the study provides an in-depth summary and forecast of the worldwide Human Mesenchymal Stem Cells (hMSC) market on the idea of several segments.

This report also delivers Human Mesenchymal Stem Cells (hMSC) market size and predicted estimations from the year 2020 to 2026 concerning various topological regions including Europe, North America, the center East and Africa, and South America. The research study on the Human Mesenchymal Stem Cells (hMSC) Market is a valuable source of guidance for world customers as it will rapidly fulfil their requirement and speed up their business growth.

It is an advantageous document for both existing industries manufactures including end-user industries, experts, managers, stakeholders and new entrants. We have designed this world Human Mesenchymal Stem Cells (hMSC) Market report in a deeply understandable format so that anyone can grasp each and every aspect related to the respective industry.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow this link:
Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research - WhaTech Technology and Markets News

UCLA

Dr. Amar Kishan

FINDINGS

Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group known as Gleason grade group 5 and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences. The findings may affect how people are treated for the disease.

One subtype, which accounts for about 15% of the grade group 5 cancers, has highly aggressive features and is associated with much worse outcomes than the other subtypes. Another, which makes up about 20% of the tumors, appears to be much less aggressive and may not require intensified and aggressive treatments. Traditionally, all tumors in Gleason grade group 5 have been treated in the same way.

BACKGROUND

Prostate cancer is the leading solid-tumor cancer among men in the United States and a major cause of morbidity globally. While early-stage, localized prostate cancer is curable, current treatments dont always work for everyone. To find out why standard treatment may work for some and not others, the UCLA researchers looked at tumors in the Gleason grade group 5 subset of prostate cancer. These tumors are at the highest risk to fail standard treatment, leading to metastasis and death. The researchers thought that studying the gene expression the unique signature of each cancer cell in these tumors might provide insight into how to make treatments more personalized for each patient.

METHOD

The researchers first analyzed data from more than 2,100 Gleason grade group 5 tumors, looking at how the genetic blueprints differed among the tumors. They identified distinct clusters of subgroups and validated their findings by analyzing an additional cohort of more than 1,900 Gleason grade group 5 prostate cancers.

IMPACT

By using the genetic information from tumors in men with prostate cancer, physicians hope to one day create more personalized treatments based on the actual characteristics of the cancer. This information will help optimize quality of life and avoid overtreating subgroups of men who may not need aggressive treatments.

AUTHORS

The studys lead author is Dr. Amar Kishan, an assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center. The co-senior authors are Dr. Joanne Weidhaas, a professor of radiation oncology and director of translational research at the Geffen School of Medicine, and Paul Boutros, a professor of urology and human genetics and director of cancer data science for the Jonsson Cancer Center. Boutros is also a member of the UCLA Institute of Urologic Oncology and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCLA. Other UCLA authors include David Elashoff, Dr. Rob Reiter and Dr. Matthew Rettig.

JOURNAL

The study was published in the journal European Urology.

FUNDING

The research was funded in part by an award from the American Society for Radiation Oncology and the Prostate Cancer Foundation, the Radiological Society of North America, and the National Institutes of Health.

Go here to see the original:
Some types of prostate cancer may not be as aggressive as originally thought - Mirage News

When people first started to get sick, the focus was on those organs, he said. But that started to shift as health workers saw first thousands and now millions of patients with COVID-19, including many whose symptoms didnt fit the typical profile of a respiratory disease.

Patients were showing up with blood clots, strokes, brain swelling and, on the more mild end of the spectrum, toe pain.

The authors approached their study like a crime scene investigation, trying to figure out why all these strange symptoms were happening, Li said.

And looking at these tissues, what we found was that the respiratory virus had not only infected the lung, but the virus had also made a beeline for the cells lining blood vessels, he said.

When those endothelial cells are damaged by the virus, it makes the blood more likely to clot, he said.

The studys authors saw from close-up pictures that the virus had moved from the air sacs of the lungs, infecting directly into the blood vessel cells.

The cells were being destroyed from the inside out, unlike when someone has high cholesterol and theyre damaged from the outside. There was emergency blood vessel growth as they divided to get more blood flow, which can lead to clots. The immune system trying to clear the virus can also cause inflammation and clotting.

So this is sort of three strikes that we saw in our study to help explain this clotting, Li said.

The damage was found in vast areas of the lungs at the same time, he added, and not just a few pockets.

Thats not something that we normally see with respiratory virus, and it seems to be unique to COVID-19.

His study also looked at the lungs of people who had died from H1N1, and found they had nine times fewer blood clots in the lungs.

An April paper in The Lancet also showed damage to endothelial cells in several areas of the body including the lungs, heart, kidneys, liver and intestines of COVID-19 patients.

Isaac Bogoch, an infectious diseases specialist at the University of Toronto and University Health Network, said he hasnt seen any COVID toes yet but has seen some vascular symptoms such as blood clots, in patients at Toronto General. Its not uncommon for diseases to have an inflammatory component, he said.

Cat-scratch disease, a bacterial infection caused by cats who turn on their owners, is one example.

But its important to remember that most people dont get a blood clot, he said, adding that within hospitals doctors are still seeing blood clots in some individuals but certainly not most individuals.

Lis research might help explain, though, why older people and those with conditions like diabetes or heart disease tend to have worse outcomes. Their blood vessels are already more vulnerable.

And it does open some new doors of thinking about treatments, Li said.

Blood thinners could be one example. There are also ongoing clinical trials looking at dilating the blood vessels with nitric oxide, and stem cell treatments to regenerate the cells. Its also important to remember that maintaining a nutritious diet can help keep blood vessels healthy, he added.

A New England Journal of Medicine paper from early May looked at outcomes of 8,910 patients across Asia, North America and Europe. It found that the use of either ACE inhibitors (medications that dilate blood vessels) or statins (drugs that help lower cholesterol) was associated with better survival. But the study could not prove a cause-and-effect relationship as it was not a randomized, controlled trial.

Researchers still dont know why COVID-19 is so much worse for some seemingly healthy people than for others, at what point the blood vessel damage starts to occur, and why blood vessels are affected in some parts of the body but not others.

The unknowns of this disease still far outnumber the knowns, so it will take time to construct the full picture of how the SARS- COV2 virus actually causes COVID-19, Li said. But blood clotting could help explain COVID toes, as well as more serious symptoms like strokes.

Multisystem inflammatory syndrome, which has been diagnosed in a small number of kids and teens who test positive for COVID-19 or antibodies that suggest they had it, may also be connected to blood vessel damage, he added.

Luckily, Jake didnt experience any severe issues, but he did have an on-and-off fever. Hes the only one in his family who had the COVID toes. His dad, Jeff, said he had the heavy, heavy chest and didnt feel like he had a full set of lungs but was lucky it didnt get more serious. His younger sister Ella had a low-grade fever for several days, but his mom and two other siblings didnt notice anything out of the ordinary.

They were told by doctors, who diagnosed Jakes toes through virtual visits, to assume they all had it, said Jeff. And their family shows the wide range of effects the disease can have on different people.

Weve got four kids, so we have a larger sample size, he said with a laugh. Weve shared air amongst us and 50 per cent had issues and 50 per cent didnt.

The Reymer family was initially told not to go for testing and just to keep self-isolating. By the time Jake and his father did get tested weeks later, when it opened up to people with more unusual symptoms, they were both negative, possibly because the virus had already cleared from their systems. The province is now urging anyone with even one mild symptom, including loss of taste and smell, and COVID toes, to get a test, as well as asymptomatic people who work in front-line jobs or think they may have been exposed.

Jake is now back to playing basketball and walking around the neighbourhood. Hes feeling good and his toes seem to be improving. But theyre still purple.

They havent shown any real signs of resolving, he said.

Im 100 per cent, its just my toes still arent normal.

May Warren is a Toronto-based breaking news reporter for the Star. Follow her on Twitter: @maywarren11

See the article here:
Is COVID-19 actually a disease of the blood vessels? New research could help explain odd symptoms from strokes to purple toes - The Flamborough Review

NICE ink developed by Texas A&M researchers can be used to 3D print customizable craniofacial implants.

Courtesy of Akhilesh Gaharwar

Subtle variations in the architecture of the 22 bones of the skull give each one of us a unique facial profile. So repairing the shape of skull defects, in the event of a fracture or a congenital deformity, calls for a technique that can be tailored to an individuals face or head structure.

In a new study, researchers at Texas A&M University have combined 3D printing, biomaterial engineering and stem cell biology to create superior, personalized bone grafts. When implanted at the site of repair, the researchers said these grafts will not only facilitate bone cells to regrow vigorously, but also serve as a sturdy platform for bone regeneration in a desired, custom shape.

Materials used for craniofacial bone implants are either biologically inactive and extremely hard, like titanium, or biologically active and too soft, like biopolymers, said Roland Kaunas, associate professor in the Department of Biomedical Engineering. In our study, we have developed a synthetic polymer that is both bioactive and mechanically strong. These materials are also 3D printable, allowing custom-shaped craniofacial implants to be made that are both aesthetically pleasing and functional.

A detailed report on the findings was published online in the journalAdvanced Healthcare Materialsin March.

Each year, about 200,000 injuries occur to bones of the jaw, face and head. For repair, physicians often hold these broken bones in place using titanium plates and screws so that surrounding bone cells can grow and form a cover around the metal implant. Despite its overall success in aiding bone repair, one of the major drawbacks of titanium is that it does not always integrate into bone tissue, which can then cause the implant to fail, requiring another surgery in advanced cases.

Thus, biocompatible polymers, particularly a type called hydrogels, offer a preferable alternative to metal implants. These squishy materials can be loaded with bone stems cells and then 3D printed to any desired shape. Also, unlike titanium plates, the body can degrade hydrogels over time. However, hydrogels also have a known weakness.

Although the pliability of hydrogel-based materials makes them good inks for 3D bioprinting, their softness compromises the mechanical integrity of the implant and the accuracy of printed parts, said Akhilesh Gaharwar, associate professor in the Department of Biomedical Engineering.

To increase the stiffness of the hydrogel, the researchers developed a nanoengineered ionic-covalent entanglement or NICE recipe containing just three main ingredients: an extract from seaweed called kappa carrageenan, gelatin and nanosilicate particles that both stimulate bone growth and mechanically reinforce the NICE hydrogel.

First, they uniformly mixed the gelatin and kappa carrageenan at microscopic scales and then added the nanosilicates. Gaharwar said the chemical bonds between these three items created a much stiffer hydrogel for 3D bioprinting with an almost eight-fold increase in strength compared to individual components of NICE bioink.

Next, they added adult stem cells to 3D parts printed with NICE ink and then chemically induced the stem cells to convert into bone cells. Within a couple of weeks, the researchers found that the cells had grown in numbers, producing high levels of bone-associated proteins, minerals and other molecules. In aggregate, these cell secretions formed a scaffold, known as an extracellular matrix, with a unique composition of biological materials needed for the growth and survival of developing bone cells.

When the scaffolds are fully developed, the researchers noted that the bone cells could be removed from the scaffold and the hydrogel-based implant can then be inserted into the site of skull injury where the surrounding, healthy bones initiate healing.Over time, the 3D printed scaffolds biodegrade, leaving behind a healed bone in the right shape.

The idea is to have the bodys own bone repair machinery participate in the repair process, Kaunas said. Our biomaterial is enriched with this regenerative extracellular matrix, providing a fertile environment to naturally trigger bone and tissue restoration.

The researchers said that the 3D-printed scaffolds provide a strong structural framework that facilitates the attachment and growth of healthy bone cells. Also, they found that developing bone cells penetrate through the synthetic material, thereby increasing the functionality of the implant.

Although our current work is focused on repairing skull bones, in the near future, we would like to expand this technology for not just craniomaxillofacial defects but also bone regeneration in cases of spinal fusions and other injuries, Kaunas said.

Other contributors to this study include Candice Sears, Eli Mondragon, Zachary Richards, Nick Sears and David Chimene from the Texas A&M Department of Biomedical Engineering; and Eoin McNeill and Carl A. Gregory from the Texas A&M Health Science Center.

This research is funded by the National Institutes of Health and the National Science Foundation.

See the rest here:
Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts - Texas A&M University Today

A team of researchers has generated a developmental map of a key sound-sensing structure in the mouse inner ear. Scientists at the National Institute on Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health, and their collaborators analyzed data from 30,000 cells from mouse cochlea, the snail-shaped structure of the inner ear. The results provide insights into the genetic programs that drive the formation of cells important for detecting sounds. The study also sheds light specifically on the underlying cause of hearing loss linked to Ehlers-Danlos syndrome and Loeys-Dietz syndrome.

The study data is shared on a unique platform open to any researcher, creating an unprecedented resource that could catalyze future research on hearing loss. Led by Matthew W. Kelley, Ph.D., chief of the Section on Developmental Neuroscience at the NIDCD, the study appeared online in Nature Communications(link is external). The research team includes investigators at the University of Maryland School of Medicine, Baltimore; Decibel Therapeutics, Boston; and Kings College London.

Unlike many other types of cells in the body, the sensory cells that enable us to hear do not have the capacity to regenerate when they become damaged or diseased, said NIDCD Director Debara L. Tucci, M.D., who is also an otolaryngology-head and neck surgeon. By clarifying our understanding of how these cells are formed in the developing inner ear, this work is an important asset for scientists working on stem cell-based therapeutics that may treat or reverse some forms of inner ear hearing loss.

In mammals, the primary transducers of sound are hair cells, which are spread across a thin ribbon of tissue (the organ of Corti) that runs the length of the coiled cochlea. There are two kinds of hair cells, inner hair cells and outer hair cells, and they are structurally and functionally sustained by several types of supporting cells. During development, a pool of nearly identical progenitor cells gives rise to these different cell types, but the factors that guide the transformation of progenitors into hair cells are not fully understood.

To learn more about how the cochlea forms, Kelleys team took advantage of a method called single-cell RNA sequencing. This powerful technique enables researchers to analyze the gene activity patterns of single cells. Scientists can learn a lot about a cell from its pattern of active genes because genes encode proteins, which define a cells function. Cells gene activity patterns change during development or in response to the environment.

There are only a few thousand hair cells in the cochlea, and they are arrayed close together in a complex mosaic, an arrangement that makes the cells hard to isolate and characterize, said Kelley. Single-cell RNA sequencing has provided us with a valuable tool to track individual cells behaviors as they take their places in the intricate structure of the developing cochlea.

Building on their earlier work on 301 cells, Kelleys team set out to examine the gene activity profiles of 30,000 cells from mouse cochleae collected at four time points, beginning with the 14th day of embryonic development and ending with the seventh postnatal day. Collectively, the data represents a vast catalog of information that researchers can use to explore cochlear development and to study the genes that underlie inherited forms of hearing impairment.

Kelleys team focused on one such gene, Tgfbr1, which has been linked to two conditions associated with hearing loss, Ehlers-Danlos syndrome and Loeys-Dietz syndrome. The data showed that Tgfbr1 is active in outer hair cell precursors as early as the 14th day of embryonic development, suggesting that the gene is important for initiating the formation of these cells.

To explore Tgfbr1s role, the researchers blocked the Tgfbr1 proteins activity in cochleae from 14.5-day-old mouse embryos. When they examined the cochleae five days later, they saw fewer outer hair cells compared to the embryonic mouse cochleae that had not been treated with the Tgfbr1 blocker. This finding suggests that hearing loss in people with Tgfbr1 mutations could stem from impaired outer hair cell formation during development.

The study revealed additional insights into the early stages of cochlear development. The developmental pathways of inner and outer hair cells diverge early on; researchers observed distinct gene activity patterns at the earliest time point in the study, the 14th day of embryonic development. This suggests that the precursors from which these cells derive are not as uniform as previously believed. Additional research on cells collected at earlier stages is needed to characterize the initial steps in the formation of hair cells.

In the future, scientists may be able to use the data to steer stem cells toward the hair cell lineage, helping to produce the specialized cells they need to test cell replacement approaches for reversing some forms of hearing loss. The studys results also represent a valuable resource for research on the hearing mechanism and how it goes awry in congenital forms of hearing loss.

The authors have made their data available through the gEAR portal(link is external) (gene Expression Analysis Resource), a web-based platform for sharing, visualizing, and analyzing large multiomic datasets. The portal is maintained by Ronna Hertzano, M.D., Ph.D., and her team in the Department of Otorhinolaryngology and the Institute for Genome Sciences (IGS)(link is external) at the University of Maryland School of Medicine.

Single-cell RNA sequencing data are highly complex and typically require significant skill to access, said Hertzano. By disseminating this study data via the gEAR, we are creating an encyclopedia of the genes expressed in the developing inner ear, transforming the knowledge base of our field and making this robust information open and understandable to biologists and other researchers.

This news release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process; each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge gained through basic research.

Reference: Kolla, L., Kelly, M. C., Mann, Z. F., Anaya-Rocha, A., Ellis, K., Lemons, A., Palermo, A. T., So, K. S., Mays, J. C., Orvis, J., Burns, J. C., Hertzano, R., Driver, E. C., & Kelley, M. W. (2020). Characterization of the development of the mouse cochlear epithelium at the single cell level. Nature Communications, 11(1), 116. https://doi.org/10.1038/s41467-020-16113-y

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Originally posted here:
30,000-cell Study Maps the Development of Sound Sensing in the Mouse Inner Ear - Technology Networks

The Stem Cell Therapy market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2026.

The report mainly studies the size, recent trends and development status of the Stem Cell Therapy market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Stem Cell Therapy market.

Download PDF Sample of Stem Cell Therapy Market report @ https://www.arcognizance.com/enquiry-sample/1030514

Major Players in the global Stem Cell Therapy market include:, Holostem Terapie Avanzate, Osiris Therapeutics, NuVasive, BIOTIME, Advanced Cell Technology, Caladrius, Pharmicell, JCR Pharmaceuticals, RTI Surgical, AlloSource, MEDIPOST, Anterogen, BrainStorm Cell Therapeutics

On the basis of types, the Stem Cell Therapy market is primarily split into:, Autologous, Allogeneic

On the basis of applications, the market covers:, Musculoskeletal disorders, Wounds and injuries, Cardiovascular diseases, Surgeries, Gastrointestinal diseases, Other applications

Brief about Stem Cell Therapy Market Report with [emailprotected] https://www.arcognizance.com/report/global-stem-cell-therapy-market-report-2019-competitive-landscape-trends-and-opportunities

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2014-2026) of the following regions:, United States, Europe (Germany, UK, France, Italy, Spain, Russia, Poland), China, Japan, India , Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam), Central and South America (Brazil, Mexico, Colombia), Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria), Other Regions

Chapter 1 provides an overview of Stem Cell Therapy market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of Stem Cell Therapy market by type, application, and region are also presented in this chapter.

Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.

Chapter 3 provides a full-scale analysis of major players in Stem Cell Therapy industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.

Chapter 4 gives a worldwide view of Stem Cell Therapy market. It includes production, market share revenue, price, and the growth rate by type.

Chapter 5 focuses on the application of Stem Cell Therapy, by analyzing the consumption and its growth rate of each application.

Chapter 6 is about production, consumption, export, and import of Stem Cell Therapy in each region.

Chapter 7 pays attention to the production, revenue, price and gross margin of Stem Cell Therapy in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.

Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.

Chapter 9 introduces the industrial chain of Stem Cell Therapy. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.

Chapter 10 provides clear insights into market dynamics.

Chapter 11 prospects the whole Stem Cell Therapy market, including the global production and revenue forecast, regional forecast. It also foresees the Stem Cell Therapy market by type and application.

Chapter 12 concludes the research findings and refines all the highlights of the study.

Chapter 13 introduces the research methodology and sources of research data for your understanding.

Years considered for this report:, Historical Years: 2014-2018, Base Year: 2019, Estimated Year: 2019, Forecast Period: 2019-2026,

Some Point of Table of Content:

Chapter One: Stem Cell Therapy Market Overview

Chapter Two: Global Stem Cell Therapy Market Landscape by Player

Chapter Three: Players Profiles

Chapter Four: Global Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

Chapter Five: Global Stem Cell Therapy Market Analysis by Application

Chapter Six: Global Stem Cell Therapy Production, Consumption, Export, Import by Region (2014-2019)

Chapter Seven: Global Stem Cell Therapy Production, Revenue (Value) by Region (2014-2019)

Chapter Eight: Stem Cell Therapy Manufacturing Analysis

Chapter Nine: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Stem Cell Therapy Market Forecast (2019-2026)

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Appendix continued

List of tablesList of Tables and FiguresFigure Stem Cell Therapy Product PictureTable Global Stem Cell Therapy Production and CAGR (%) Comparison by TypeTable Profile of AutologousTable Profile of AllogeneicTable Stem Cell Therapy Consumption (Sales) Comparison by Application (2014-2026)Table Profile of Musculoskeletal disordersTable Profile of Wounds and injuriesTable Profile of Cardiovascular diseasesTable Profile of SurgeriesTable Profile of Gastrointestinal diseasesTable Profile of Other applicationsFigure Global Stem Cell Therapy Market Size (Value) and CAGR (%) (2014-2026)Figure United States Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Europe Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Germany Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure UK Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure France Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Italy Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Spain Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Russia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Poland Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure China Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Japan Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure India Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Southeast Asia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Malaysia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Singapore Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Philippines Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Indonesia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Thailand Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Vietnam Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Central and South America Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Brazil Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Mexico Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Colombia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Middle East and Africa Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Saudi Arabia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure United Arab Emirates Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Turkey Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Egypt Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure South Africa Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Nigeria Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Global Stem Cell Therapy Production Status and Outlook (2014-2026)Table Global Stem Cell Therapy Production by Player (2014-2019)Table Global Stem Cell Therapy Production Share by Player (2014-2019)Figure Global Stem Cell Therapy Production Share by Player in 2018Table Stem Cell Therapy Revenue by Player (2014-2019)Table Stem Cell Therapy Revenue Market Share by Player (2014-2019)Table Stem Cell Therapy Price by Player (2014-2019)Table Stem Cell Therapy Manufacturing Base Distribution and Sales Area by PlayerTable Stem Cell Therapy Product Type by PlayerTable Mergers & Acquisitions, Expansion PlansTable Holostem Terapie Avanzate ProfileTable Holostem Terapie Avanzate Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Osiris Therapeutics ProfileTable Osiris Therapeutics Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table NuVasive ProfileTable NuVasive Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table BIOTIME ProfileTable BIOTIME Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Advanced Cell Technology ProfileTable Advanced Cell Technology Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Caladrius ProfileTable Caladrius Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Pharmicell ProfileTable Pharmicell Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table JCR Pharmaceuticals ProfileTable JCR Pharmaceuticals Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table RTI Surgical ProfileTable RTI Surgical Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table AlloSource ProfileTable AlloSource Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table MEDIPOST ProfileTable MEDIPOST Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Anterogen ProfileTable Anterogen Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table BrainStorm Cell Therapeutics ProfileTable BrainStorm Cell Therapeutics Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Global Stem Cell Therapy Production by Type (2014-2019)Table Global Stem Cell Therapy Production Market Share by Type (2014-2019)Figure Global Stem Cell Therapy Production Market Share by Type in 2018Table Global Stem Cell Therapy Revenue by Type (2014-2019)Table Global Stem Cell Therapy Revenue Market Share by Type (2014-2019)Figure Global Stem Cell Therapy Revenue Market Share by Type in 2018Table Stem Cell Therapy Price by Type (2014-2019)Figure Global Stem Cell Therapy Production Growth Rate of Autologous (2014-2019)Figure Global Stem Cell Therapy Production Growth Rate of Allogeneic (2014-2019)Table Global Stem Cell Therapy Consumption by Application (2014-2019)Table Global Stem Cell Therapy Consumption Market Share by Application (2014-2019)Table Global Stem Cell Therapy Consumption of Musculoskeletal disorders (2014-2019)Table Global Stem Cell Therapy Consumption of Wounds and injuries (2014-2019)Table Global Stem Cell Therapy Consumption of Cardiovascular diseases (2014-2019)Table Global Stem Cell Therapy Consumption of Surgeries (2014-2019)Table Global Stem Cell Therapy Consumption of Gastrointestinal diseases (2014-2019)Table Global Stem Cell Therapy Consumption of Other applications (2014-2019)Table Global Stem Cell Therapy Consumption by Region (2014-2019)Table Global Stem Cell Therapy Consumption Market Share by Region (2014-2019)Table United States Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Europe Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table China Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Japan Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table India Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Southeast Asia Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Central and South America Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)continued

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

See the original post here:
Global Stem Cell Therapy Market 2020 Research Report Insights and Analysis, Forecast to 2026 - 3rd Watch News